RB binding protein 9, serine hydrolaseGenealiases: BOG · RBBP10
Q-omics provides the consensus-scored RBBP9 profile across patient tissues and cancer cell-line models. RBBP9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RBBP9 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, RBBP9 protein abundance shows 22,722 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KICH, and PDAC as cancer lineages where RBBP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBBP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBBP9 survival associations across molecular data types. RBBP9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBBP9 RNA expression–survival associations across cancer types. High RBBP9 expression shows unfavorable associations in ACC and LGG, but favorable associations in HNSC, KIRC, BRCA and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for RBBP9 RNA expression.
This table summarizes RBBP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RBBP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBBP9 shows lower tumor expression in KICH and higher tumor expression in BLCA, BRCA, COAD, STAD and CHOL. The KICH box plot shows higher RBBP9 RNA expression in normal versus tumor tissue (log2 FC = −2.542, t-test p < 0.001).
This table shows molecular features associated with RBBP9 in patient tissues and cancer cell lines. In patient samples, RBBP9 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBBP9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
